Skandinaviska Enskilda Banken AB publ Sells 32,500 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Skandinaviska Enskilda Banken AB publ cut its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 77.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 9,500 shares of the medical equipment provider’s stock after selling 32,500 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Lantheus were worth $847,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Raymond James Financial Inc. bought a new position in shares of Lantheus during the 4th quarter worth about $36,183,000. Groupama Asset Managment bought a new position in Lantheus in the third quarter worth approximately $439,000. Swedbank AB grew its stake in Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock valued at $99,054,000 after acquiring an additional 385,000 shares during the period. Keybank National Association OH bought a new stake in shares of Lantheus during the fourth quarter valued at approximately $27,526,000. Finally, Janus Henderson Group PLC raised its position in shares of Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after purchasing an additional 257,022 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Lantheus

In other news, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now owns 440,399 shares in the company, valued at approximately $41,551,645.65. This represents a 10.76 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 54,109 shares of company stock valued at $5,105,606. Company insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. The Goldman Sachs Group initiated coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. Truist Financial increased their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Finally, JMP Securities reissued a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $132.86.

Lantheus Stock Performance

Shares of NASDAQ:LNTH opened at $102.76 on Tuesday. The company has a market capitalization of $7.04 billion, a P/E ratio of 17.10 and a beta of 0.38. The company’s 50-day moving average is $92.25 and its 200 day moving average is $96.67. Lantheus Holdings, Inc. has a fifty-two week low of $56.44 and a fifty-two week high of $126.89.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. As a group, research analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.